{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,10]],"date-time":"2026-04-10T01:41:09Z","timestamp":1775785269558,"version":"3.50.1"},"reference-count":50,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2025,12,1]],"date-time":"2025-12-01T00:00:00Z","timestamp":1764547200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,12,1]],"date-time":"2025-12-01T00:00:00Z","timestamp":1764547200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,12,1]],"date-time":"2025-12-01T00:00:00Z","timestamp":1764547200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2025,12,1]],"date-time":"2025-12-01T00:00:00Z","timestamp":1764547200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2025,12,1]],"date-time":"2025-12-01T00:00:00Z","timestamp":1764547200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2025,12,1]],"date-time":"2025-12-01T00:00:00Z","timestamp":1764547200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2025,12,1]],"date-time":"2025-12-01T00:00:00Z","timestamp":1764547200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["31670937"],"award-info":[{"award-number":["31670937"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["International Immunopharmacology"],"published-print":{"date-parts":[[2025,12]]},"DOI":"10.1016\/j.intimp.2025.115648","type":"journal-article","created":{"date-parts":[[2025,10,15]],"date-time":"2025-10-15T15:49:38Z","timestamp":1760543378000},"page":"115648","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":1,"special_numbering":"C","title":["Enhancement of antitumor immunity by CTLA-4 antisense oligonucleotides with CpG motif in mice"],"prefix":"10.1016","volume":"167","author":[{"given":"Kuo","family":"Qu","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mengru","family":"Zhu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Feiyu","family":"Lu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tong","family":"Zhu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tingli","family":"Wang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Liying","family":"Wang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yongli","family":"Yu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"8","key":"10.1016\/j.intimp.2025.115648_bb0005","doi-asserted-by":"crossref","first-page":"1652","DOI":"10.1016\/j.cell.2023.03.006","article-title":"Immune checkpoint therapy-current perspectives and future directions","volume":"186","author":"Sharma","year":"2023","journal-title":"Cell"},{"issue":"9","key":"10.1016\/j.intimp.2025.115648_bb0010","doi-asserted-by":"crossref","first-page":"3377","DOI":"10.1172\/JCI80012","article-title":"Cytotoxic T lymphocyte antigen-4 and immune checkpoint blockade","volume":"125","author":"Buchbinder","year":"2015","journal-title":"J. Clin. Invest."},{"issue":"5256","key":"10.1016\/j.intimp.2025.115648_bb0015","doi-asserted-by":"crossref","first-page":"1734","DOI":"10.1126\/science.271.5256.1734","article-title":"Enhancement of antitumor immunity by CTLA-4 blockade","volume":"271","author":"Leach","year":"1996","journal-title":"Science"},{"issue":"3","key":"10.1016\/j.intimp.2025.115648_bb0020","doi-asserted-by":"crossref","first-page":"434","DOI":"10.1016\/j.immuni.2018.03.014","article-title":"Regulation and function of the PD-L1 checkpoint","volume":"48","author":"Sun","year":"2018","journal-title":"Immunity"},{"issue":"5","key":"10.1016\/j.intimp.2025.115648_bb0025","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2024-008799","article-title":"Combining toll-like receptor agonists with immune checkpoint blockade affects antitumor vaccine efficacy","volume":"12","author":"Jeon","year":"2024","journal-title":"J. Immunother. Cancer"},{"issue":"8","key":"10.1016\/j.intimp.2025.115648_bb0030","doi-asserted-by":"crossref","first-page":"711","DOI":"10.1056\/NEJMoa1003466","article-title":"Improved survival with ipilimumab in patients with metastatic melanoma","volume":"363","author":"Hodi","year":"2010","journal-title":"N. Engl. J. Med."},{"issue":"10","key":"10.1016\/j.intimp.2025.115648_bb0035","doi-asserted-by":"crossref","first-page":"2861","DOI":"10.1158\/1078-0432.CCR-10-0569","article-title":"Preoperative CTLA-4 blockade: tolerability and immune monitoring in the setting of a presurgical clinical trial","volume":"16","author":"Carthon","year":"2010","journal-title":"Clin. Cancer Res."},{"issue":"17","key":"10.1016\/j.intimp.2025.115648_bb0040","doi-asserted-by":"crossref","first-page":"1889","DOI":"10.1200\/JCO.2014.56.2736","article-title":"Pooled analysis of long-term survival data from phase II and phase III trials of Ipilimumab in Unresectable or metastatic melanoma","volume":"33","author":"Schadendorf","year":"2015","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.intimp.2025.115648_bb0045","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1016\/j.jconrel.2020.06.017","article-title":"Blockade of CTLA-4 increases anti-tumor response inducing potential of dendritic cell vaccine","volume":"326","author":"Esmaily","year":"2020","journal-title":"J. Control. Release"},{"issue":"7","key":"10.1016\/j.intimp.2025.115648_bb0050","doi-asserted-by":"crossref","first-page":"2977","DOI":"10.1172\/JCI73174","article-title":"CTLA4 aptamer delivers STAT3 siRNA to tumor-associated and malignant T cells","volume":"124","author":"Herrmann","year":"2014","journal-title":"J. Clin. Invest."},{"key":"10.1016\/j.intimp.2025.115648_bb0055","doi-asserted-by":"crossref","first-page":"520","DOI":"10.1016\/j.omtn.2017.08.006","article-title":"A CTLA-4 antagonizing DNA aptamer with antitumor effect","volume":"8","author":"Huang","year":"2017","journal-title":"Mol Ther Nucleic Acids"},{"issue":"2","key":"10.1016\/j.intimp.2025.115648_bb0060","doi-asserted-by":"crossref","DOI":"10.3390\/molecules26020253","article-title":"Peptide blocking CTLA-4 and B7-1 interaction","volume":"26","author":"Podlesnykh","year":"2021","journal-title":"Molecules"},{"issue":"2","key":"10.1016\/j.intimp.2025.115648_bb0065","doi-asserted-by":"crossref","first-page":"360","DOI":"10.1021\/acschembio.9b00743","article-title":"An immune-stimulatory Helix-loop-Helix peptide: selective inhibition of CTLA-4-B7 interaction","volume":"15","author":"Ramanayake Mudiyanselage","year":"2020","journal-title":"ACS Chem. Biol."},{"issue":"12","key":"10.1016\/j.intimp.2025.115648_bb0070","doi-asserted-by":"crossref","DOI":"10.3390\/ph15121506","article-title":"Rational strategy for designing Peptidomimetic small molecules based on cyclic peptides targeting protein-protein interaction between CTLA-4 and B7-1","volume":"15","author":"Tsuihiji","year":"2022","journal-title":"Pharmaceuticals (Basel)"},{"issue":"18","key":"10.1016\/j.intimp.2025.115648_bb0075","doi-asserted-by":"crossref","first-page":"2379","DOI":"10.1016\/j.vaccine.2017.03.043","article-title":"Adjuvanticity of a CTLA-4 3' UTR complementary oligonucleotide for emulsion formulated recombinant subunit and inactivated vaccines","volume":"35","author":"Li","year":"2017","journal-title":"Vaccine"},{"issue":"24","key":"10.1016\/j.intimp.2025.115648_bb0080","doi-asserted-by":"crossref","first-page":"5041","DOI":"10.1182\/blood-2009-03-213363","article-title":"Toll-like receptor 9 signaling by CpG-B oligodeoxynucleotides induces an apoptotic pathway in human chronic lymphocytic leukemia B cells","volume":"115","author":"Liang","year":"2010","journal-title":"Blood"},{"issue":"3","key":"10.1016\/j.intimp.2025.115648_bb0085","doi-asserted-by":"crossref","first-page":"426","DOI":"10.1016\/j.clim.2009.01.011","article-title":"Therapeutic injection of C-class CpG ODN in draining lymph node area induces potent activation of immune cells and rejection of established breast cancer in mice","volume":"131","author":"Yang","year":"2009","journal-title":"Clin. Immunol."},{"issue":"8","key":"10.1016\/j.intimp.2025.115648_bb0090","doi-asserted-by":"crossref","first-page":"2671","DOI":"10.1007\/s00262-023-03451-1","article-title":"Massively recruited sTLR9(+) neutrophils in rapidly formed nodules at the site of tumor cell inoculation and their contribution to a pro-tumor microenvironment","volume":"72","author":"Kou","year":"2023","journal-title":"Cancer Immunol. Immunother."},{"issue":"2","key":"10.1016\/j.intimp.2025.115648_bb0095","doi-asserted-by":"crossref","first-page":"402","DOI":"10.1016\/j.intimp.2011.12.013","article-title":"A CpG oligodeoxynucleotide potentiates the anti-tumor effect of HSP65-Her2 fusion protein against Her2 positive B16 melanoma in mice","volume":"12","author":"Yan","year":"2012","journal-title":"Int. Immunopharmacol."},{"issue":"4","key":"10.1016\/j.intimp.2025.115648_bb0100","doi-asserted-by":"crossref","first-page":"253","DOI":"10.1089\/nat.2013.0419","article-title":"Fully phosphorothioate-modified CpG ODN with PolyG motif inhibits the adhesion of B16 melanoma cells in vitro and tumorigenesis in vivo","volume":"23","author":"Wang","year":"2013","journal-title":"Nucleic Acid Ther."},{"issue":"3","key":"10.1016\/j.intimp.2025.115648_bb0105","doi-asserted-by":"crossref","first-page":"241","DOI":"10.7150\/jca.12899","article-title":"Delivery system of CpG Oligodeoxynucleotides through eliciting an effective T cell immune response against melanoma in mice","volume":"7","author":"Sun","year":"2016","journal-title":"J. Cancer"},{"issue":"5","key":"10.1016\/j.intimp.2025.115648_bb0110","doi-asserted-by":"crossref","first-page":"1103","DOI":"10.1007\/s00262-022-03315-0","article-title":"Immunotherapy for lung cancer combining the oligodeoxynucleotides of TLR9 agonist and TGF-beta2 inhibitor","volume":"72","author":"Yao","year":"2023","journal-title":"Cancer Immunol. Immunother."},{"issue":"10","key":"10.1016\/j.intimp.2025.115648_bb0115","doi-asserted-by":"crossref","first-page":"4213","DOI":"10.1007\/s00253-021-11316-9","article-title":"CpG ODN as an adjuvant arouses the vigor of B cells by relieving the negative regulation of surface TLR9 to enhance the antibody response to vaccine","volume":"105","author":"Lu","year":"2021","journal-title":"Appl. Microbiol. Biotechnol."},{"issue":"11","key":"10.1016\/j.intimp.2025.115648_bb0120","doi-asserted-by":"crossref","first-page":"6635","DOI":"10.4049\/jimmunol.165.11.6635","article-title":"Quantitative genetic variation in CD19 expression correlates with autoimmunity","volume":"165","author":"Sato","year":"2000","journal-title":"J. Immunol."},{"key":"10.1016\/j.intimp.2025.115648_bb0125","doi-asserted-by":"crossref","first-page":"515","DOI":"10.1146\/annurev.immunol.23.021704.115611","article-title":"The B7 family revisited","volume":"23","author":"Greenwald","year":"2005","journal-title":"Annu. Rev. Immunol."},{"key":"10.1016\/j.intimp.2025.115648_bb0130","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1016\/j.cytogfr.2023.11.002","article-title":"Harnessing the potential of CD40 agonism in cancer therapy","volume":"75","author":"Zhou","year":"2024","journal-title":"Cytokine Growth Factor Rev."},{"issue":"7","key":"10.1016\/j.intimp.2025.115648_bb0135","doi-asserted-by":"crossref","first-page":"795","DOI":"10.1016\/j.addr.2007.12.004","article-title":"TLR9 as a key receptor for the recognition of DNA","volume":"60","author":"Kumagai","year":"2008","journal-title":"Adv. Drug Deliv. Rev."},{"key":"10.1016\/j.intimp.2025.115648_bb0140","doi-asserted-by":"crossref","first-page":"191","DOI":"10.1146\/annurev.iy.11.040193.001203","article-title":"The role of the CD28 receptor during T cell responses to antigen","volume":"11","author":"Linsley","year":"1993","journal-title":"Annu. Rev. Immunol."},{"issue":"6","key":"10.1016\/j.intimp.2025.115648_bb0145","doi-asserted-by":"crossref","first-page":"930","DOI":"10.1016\/j.ccell.2024.05.015","article-title":"Let it be: preserving tumor-draining lymph nodes in the era of immuno-oncology","volume":"42","author":"Saddawi-Konefka","year":"2024","journal-title":"Cancer Cell"},{"issue":"1","key":"10.1016\/j.intimp.2025.115648_bb0150","doi-asserted-by":"crossref","first-page":"2","DOI":"10.1186\/s12864-019-6344-3","article-title":"Comparison of the molecular and cellular phenotypes of common mouse syngeneic models with human tumors","volume":"21","author":"Zhong","year":"2020","journal-title":"BMC Genomics"},{"key":"10.1016\/j.intimp.2025.115648_bb0155","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1146\/annurev.immunol.24.021605.090535","article-title":"A molecular perspective of CTLA-4 function","volume":"24","author":"Teft","year":"2006","journal-title":"Annu. Rev. Immunol."},{"issue":"1","key":"10.1016\/j.intimp.2025.115648_bb0160","doi-asserted-by":"crossref","first-page":"60","DOI":"10.1016\/j.bbagrm.2007.10.004","article-title":"The 3\u2019 UTR of the human CTLA4 mRNA can regulate mRNA stability and translational efficiency","volume":"1779","author":"Malquori","year":"2008","journal-title":"Biochim. Biophys. Acta"},{"issue":"2","key":"10.1016\/j.intimp.2025.115648_bb0165","article-title":"Small drugs, huge impact: the extraordinary impact of antisense oligonucleotides in research and drug development","volume":"27","author":"A.M. Quemener, M.L. Centomo, S.L. Sax, R. Panella","year":"2022","journal-title":"Molecules"},{"issue":"Web Server issue","key":"10.1016\/j.intimp.2025.115648_bb0170","doi-asserted-by":"crossref","first-page":"W135","DOI":"10.1093\/nar\/gkh449","article-title":"Sfold web server for statistical folding and rational design of nucleic acids","volume":"32","author":"Ding","year":"2004","journal-title":"Nucleic Acids Res."},{"issue":"4","key":"10.1016\/j.intimp.2025.115648_bb0175","first-page":"379","article-title":"Cellular distribution of phosphorothioate oligodeoxynucleotides in normal rodent tissues","volume":"77","author":"Butler","year":"1997","journal-title":"Lab. Invest."},{"issue":"6","key":"10.1016\/j.intimp.2025.115648_bb0180","doi-asserted-by":"crossref","first-page":"471","DOI":"10.1038\/nrd2059","article-title":"Therapeutic potential of toll-like receptor 9 activation","volume":"5","author":"Krieg","year":"2006","journal-title":"Nat. Rev. Drug Discov."},{"issue":"10","key":"10.1016\/j.intimp.2025.115648_bb0185","doi-asserted-by":"crossref","first-page":"898","DOI":"10.1158\/2326-6066.CIR-17-0075","article-title":"Antigen-presenting Intratumoral B cells affect CD4(+) TIL phenotypes in non-small cell lung Cancer patients","volume":"5","author":"Bruno","year":"2017","journal-title":"Cancer Immunol. Res."},{"issue":"7","key":"10.1016\/j.intimp.2025.115648_bb0190","doi-asserted-by":"crossref","first-page":"4006","DOI":"10.4049\/jimmunol.0903009","article-title":"B cells are required for optimal CD4+ and CD8+ T cell tumor immunity: therapeutic B cell depletion enhances B16 melanoma growth in mice","volume":"184","author":"DiLillo","year":"2010","journal-title":"J. Immunol."},{"issue":"71","key":"10.1016\/j.intimp.2025.115648_bb0195","doi-asserted-by":"crossref","first-page":"eabn5859","DOI":"10.1126\/sciimmunol.abn5859","article-title":"Intratumoral immunotherapy relies on B and T cell collaboration","volume":"7","author":"Sagiv-Barfi","year":"2022","journal-title":"Sci Immunol"},{"issue":"7791","key":"10.1016\/j.intimp.2025.115648_bb0200","doi-asserted-by":"crossref","first-page":"556","DOI":"10.1038\/s41586-019-1906-8","article-title":"B cells are associated with survival and immunotherapy response in sarcoma","volume":"577","author":"Petitprez","year":"2020","journal-title":"Nature"},{"issue":"7791","key":"10.1016\/j.intimp.2025.115648_bb0205","doi-asserted-by":"crossref","first-page":"549","DOI":"10.1038\/s41586-019-1922-8","article-title":"B cells and tertiary lymphoid structures promote immunotherapy response","volume":"577","author":"Helmink","year":"2020","journal-title":"Nature"},{"issue":"7","key":"10.1016\/j.intimp.2025.115648_bb0210","doi-asserted-by":"crossref","first-page":"441","DOI":"10.1038\/s41571-022-00619-z","article-title":"B cells and tertiary lymphoid structures as determinants of tumour immune contexture and clinical outcome","volume":"19","author":"Fridman","year":"2022","journal-title":"Nat. Rev. Clin. Oncol."},{"issue":"4","key":"10.1016\/j.intimp.2025.115648_bb0215","doi-asserted-by":"crossref","first-page":"227","DOI":"10.1038\/nri3405","article-title":"Molecular mechanisms of T cell co-stimulation and co-inhibition","volume":"13","author":"Chen","year":"2013","journal-title":"Nat. Rev. Immunol."},{"key":"10.1016\/j.intimp.2025.115648_bb0220","doi-asserted-by":"crossref","first-page":"2737","DOI":"10.3389\/fimmu.2018.02737","article-title":"CTLA-4 and PD-1 control of T-cell motility and migration: implications for tumor immunotherapy","volume":"9","author":"Brunner-Weinzierl","year":"2018","journal-title":"Front. Immunol."},{"issue":"5","key":"10.1016\/j.intimp.2025.115648_bb0225","doi-asserted-by":"crossref","first-page":"456","DOI":"10.1001\/jamasurg.2013.1335","article-title":"Long-term follow-up and survival of patients following a recurrence of melanoma after a negative sentinel lymph node biopsy result","volume":"148","author":"Jones","year":"2013","journal-title":"JAMA Surg."},{"issue":"4","key":"10.1016\/j.intimp.2025.115648_bb0230","doi-asserted-by":"crossref","first-page":"652","DOI":"10.1016\/j.jamcollsurg.2016.12.038","article-title":"Patient symptoms are the Most frequent indicators of recurrence in patients with American joint committee on Cancer stage II melanoma","volume":"224","author":"Berger","year":"2017","journal-title":"J. Am. Coll. Surg."},{"issue":"6230","key":"10.1016\/j.intimp.2025.115648_bb0235","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1126\/science.aaa8172","article-title":"The future of immune checkpoint therapy","volume":"348","author":"Sharma","year":"2015","journal-title":"Science"},{"issue":"5","key":"10.1016\/j.intimp.2025.115648_bb0240","doi-asserted-by":"crossref","first-page":"769","DOI":"10.1007\/s11523-024-01092-7","article-title":"Norte Study, Efficacy and Safety of Durvalumab\/Tremelimumab in Unresectable Hepatocellular Carcinoma as Immune Checkpoint Inhibitor Rechallenge Following Atezolizumab\/Bevacizumab Treatment","volume":"vol. 19","author":"Sho","year":"2024","journal-title":"Target Oncol"},{"issue":"3","key":"10.1016\/j.intimp.2025.115648_bb0245","doi-asserted-by":"crossref","first-page":"535","DOI":"10.1007\/s12020-017-1289-2","article-title":"Prevalence of hypophysitis in a cohort of patients with metastatic melanoma and prostate cancer treated with ipilimumab","volume":"58","author":"Brilli","year":"2017","journal-title":"Endocrine"},{"issue":"1","key":"10.1016\/j.intimp.2025.115648_bb0250","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1038\/s41572-020-0160-6","article-title":"Immune-related adverse events of checkpoint inhibitors","volume":"6","author":"Ramos-Casals","year":"2020","journal-title":"Nat. Rev. Dis. Primers."}],"container-title":["International Immunopharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S156757692501639X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S156757692501639X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,12,11]],"date-time":"2025-12-11T12:36:31Z","timestamp":1765456591000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S156757692501639X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,12]]},"references-count":50,"alternative-id":["S156757692501639X"],"URL":"https:\/\/doi.org\/10.1016\/j.intimp.2025.115648","relation":{},"ISSN":["1567-5769"],"issn-type":[{"value":"1567-5769","type":"print"}],"subject":[],"published":{"date-parts":[[2025,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Enhancement of antitumor immunity by CTLA-4 antisense oligonucleotides with CpG motif in mice","name":"articletitle","label":"Article Title"},{"value":"International Immunopharmacology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.intimp.2025.115648","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 Elsevier B.V. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"115648"}}